Waldo Mossi, CEO, HAS Healthcare Advanced Synthesis Group, outlined the company’s expansion plan and integration of its acquisition of the CDMO Cerbios-Pharma at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week.

Mossi outlined the integration of Cerbios-Pharma, which the company acquired in 2025, to further build the company’s drug-substance capabilities. In May 2025, HAS acquired Cerbios-Pharma SA, merging under the HAS Group and providing the combined company with three manufacturing plants for CDMO services with biotech and chemical manufacturing lines. The original HAS site in Biasca, Switzerland, has development and manufacturing capabilities for active pharmaceutical ingredients (APIs), high-potency APIs (HPAPIs), and anticancer medicines and is synergistic with Cerbios-Pharma, with a site in Barbengo, Switzerland, which specializes in biological APIs and antibody drug conjugates (ADCs). The combined company has approximately 450 employees.

In addition, Mossi outlined a five-year investment (2026–2030) program exceeding $120 million that the company first announced in January (January 2026.), which includes several key expansions for ADC capabilities, HPAPIs and payloads, and R&D and API capacity upgrades.

With respect to ADC conjugation capabilities, HAS is launching a new 500-L conjugation line to be operational in April 2026, with a third 500-L line planned for 2028. The Group also aims to commission a commercial ADC building with conjugation volumes exceeding 1,000 L.

With respect to HPAPI and payload expansions, the Group is further strengthening its HPAPI capabilities with new containment systems for HPAPIs (OEL < 10 ng/m³) and a dedicated unit for downstream technologies, including chromatography, nanofiltration, and lyophilization, for ADC payloads at commercial scales.

The company is also making R&D and API capacity upgrades, which include new R&D and quality-control labs, a commercial-scale production suite (500 L–1,200 L), and additional isolation boxes and dryers to optimize the synthesis and downstream isolation processes.

The combined company has reactor ranges spanning from 5 L to 4,000 L and support temperatures from -80°C to 150°C, and production scales from early-phase development to commercial manufacturing. Looking ahead to 2030, HAS Group says it aims to position itself for the next generation of oncological and complex biological therapies.